H

Hepion Pharmaceuticals
D

HEPA

0.71440
USD
0.03
(4.75%)
Market Closed
Volume
0
EPS
-11
Div Yield
-
P/E
-0
Market Cap
4,142,896
Related Instruments
    C
    CRIS
    -0.04000
    (-1.00%)
    3.96000 USD
    M
    MRSN
    -0.31000
    (-12.30%)
    2.21000 USD
    More
News

Title: Hepion Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.